Gramenox (Piperacillin, Tazobactam)

Gramenox is indicated for the treatment of a variety of serious bacterial infections where a broad‑spectrum agent is required.

• Complicated intra‑abdominal infections, including peritonitis and abscesses.
• Hospital‑acquired or ventilator‑associated pneumonia, including Pseudomonas spp.
• Complicated urinary tract infections and pyelonephritis.
• Skin and soft‑tissue infections caused by susceptible organisms.
• Febrile neutropenia in oncology patients.

Adverse reactions to Gramenox may involve the gastrointestinal system, skin, hematologic parameters, and, rarely, severe hypersensitivity.

Common

• Diarrhea or loose stools.
• Nausea and vomiting.
• Elevated liver enzymes (ALT, AST).
• Rash or mild pruritus.
• Injection site discomfort.

Serious

• Anaphylactic or severe allergic reactions (e.g., urticaria, bronchospasm).
• Clostridioides difficile‑associated colitis.
• Seizures, especially in patients with renal impairment.
• Hemolytic anemia or thrombocytopenia.

Before initiating Gramenox, clinicians should evaluate patient history and laboratory values to minimize risk of adverse events.

• Assess renal function; dose adjustment may be required in renal impairment.
• Review allergy history for penicillin or beta‑lactam hypersensitivity.
• Monitor liver function tests during prolonged therapy.
• Use caution in patients with a history of seizures or central nervous system disorders.
• Observe for signs of superinfection, including C. difficile colitis.
• Consider pregnancy and lactation status; safety data are limited.

Gramenox can interact with other medicines, affecting efficacy or safety.

Avoid

• Concurrent use with other beta‑lactam antibiotics may increase risk of additive toxicity.
• Co‑administration with aminoglycosides can enhance nephrotoxicity.

Use with caution

• Loop diuretics may increase the risk of electrolyte disturbances.
• Anticoagulants (e.g., warfarin) may have altered INR values.
• Probenecid can reduce renal clearance of piperacillin.